The NSAID Dilemma: Managing Osteoarthritis in High-Risk Patients

References

• . Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice. Ann Intern Med. 1988;109(5):353–354
   PubMed Web of Science ®Google Scholar
• . Barkin RL, Beckerman M, Blum SL, Clark FM, Koh E, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010;27(10):775–789
   PubMed Web of Science ®Google Scholar
• . Richette P, Hilliquin P, Bertin P, Carni P, Berger V, Marty M. Comparison of general practitioners and rheumatologists' prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord. 2011;12:72
   PubMed Web of Science ®Google Scholar
• . Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk of cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011;9:38
   PubMed Web of Science ®Google Scholar
• . American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–1346
   PubMed Web of Science ®Google Scholar
• . Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–2099
   PubMedGoogle Scholar
• . Roth SH. Understanding the COX-2/NSAID dilemma. Drugs. 2005;65(14):1915–1917
   PubMedGoogle Scholar
• . Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000;321(7276):1591–1594
   PubMedGoogle Scholar
• . Pressly TA. The use of nonsteroidal anti-inflammatory medications: a therapeutic dilemma. J La State Med Soc. 1992;144(12):575–578
   PubMedGoogle Scholar
• . Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–681
   PubMed Web of Science ®Google Scholar
• . Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s–110s
   PubMed Web of Science ®Google Scholar
• . Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146(4):591–604
   PubMedGoogle Scholar
• . Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm. 2006;63(19):1837–1851
   PubMed Web of Science ®Google Scholar
• . Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs. 2009;69(1):51–69
   PubMed Web of Science ®Google Scholar
• . Thomsen RW, Riis A, Munk EM, Nørgaard M, Christensen S, Sørensen HT. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol. 2006;101(12):2704–2710
   PubMedGoogle Scholar
• . Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340(24):1888–1899
   PubMed Web of Science ®Google Scholar
• . Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26( suppl 56):18–24
   Web of Science ®Google Scholar
• . Straube S, Tramèr MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;5(9):41
   Google Scholar
• . National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. NICE clinical guideline 59. London, England: National Institutes for Health and Clinical Excellence; 2008
   Google Scholar
• . Chan FK, Abraham NS, Scheiman JM, Laine L; First International Working Party on gastrointestinal and Cardiovascular effects of Nonsteroidal Ani-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103(11):2908–2918
   PubMed Web of Science ®Google Scholar
• . Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine. 2010;77(1):6–12
   PubMedGoogle Scholar
• . Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988;84( suppl 2A):20–24
   PubMedGoogle Scholar
• . McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–1644
   PubMed Web of Science ®Google Scholar
• . Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103(9):1227–1237
   PubMed Web of Science ®Google Scholar
• . Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. 2007;23(8):1859–1866
   PubMed Web of Science ®Google Scholar
• . Solomon DH, Glynn RJ, Rothman KJ, . Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–1104
   PubMed Web of Science ®Google Scholar
• . Griffin MR, Scheiman JM. Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. Am J Med. 2001;110:33S–37S
   Web of Science ®Google Scholar
• . Fosbol EL, Gislason GH, Jacobsen S, . Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–197
   PubMed Web of Science ®Google Scholar
• . Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, . Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction. Circulation. 2011;123(20):2226–2235
   PubMed Web of Science ®Google Scholar
• . Bombardier C, Laine, Reicin A, ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000;343(21):1520–1528
   PubMed Web of Science ®Google Scholar
• . Sorensen R, Hansen ML, Abildstrom SZ, . Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967–1974
   PubMed Web of Science ®Google Scholar
• . Becker RV, Burke TA, McCoy MA, Trotter JP. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with ostearthritis and hypertension in a Medicare choice population. Clin Ther. 2003;25(2):647–662
   PubMedGoogle Scholar
• . Radford MG, Holley KE, Grande JP, . Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA. 1996;276(6):466–469
   PubMedGoogle Scholar
• . O'Brien WM, Bagby GL. Rare adverse reactions to nonsteroidal anti-inflammatory drugs. J Rheum. 1985;12:13–20
   PubMed Web of Science ®Google Scholar
• . European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs [news release]. London, England: European Medicines Agency; October 2006. Doc. Ref. EMEA/413136/2006. http://www.emea.europa.eu/pdfs/human/press/pr/41313606.pdf. Accessed August 16, 2011
   Google Scholar
• . Zhang W, Moskowitz RW, Nuki G, . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162
   PubMed Web of Science ®Google Scholar
• . American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43(9):1905–1915
   PubMed Web of Science ®Google Scholar
• . Burmester G, Lanas A, Biasucci L, . The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011;70(5):818–822
   PubMedGoogle Scholar
• . Hogan DB, Campbell NR, Crutcher R, Jennett P, MacLeod N. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J. 1994;151(3):315–322
   Google Scholar
• . Tak SH, Hong SH. Use of the Internet for health information by older adults with arthritis. Orthop Nurs. 2005;24(2):134–138
   PubMed Web of Science ®Google Scholar
• . Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003;12(4):315–326
   PubMed Web of Science ®Google Scholar
• . Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005;32(11):2218–2224
   PubMed Web of Science ®Google Scholar
• . Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemmorrhage. Arch Intern Med. 1994;154(1):42–46
   PubMed Web of Science ®Google Scholar
• . Tulner LR, Frankfort SV, Gijsen GJ, . Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343–355
   PubMed Web of Science ®Google Scholar
• . Shorr RI, Ray WA, Daughtery JR, Griffin MR. Concurrent use of NSAIDs and oral anticoagulant places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153(14):1665–1670
   PubMedGoogle Scholar
• . Ljung R, Lu Y, Lagerman J. High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population. Drugs Aging. 2011;28(6):469–476
   PubMed Web of Science ®Google Scholar
• . de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1
   PubMedGoogle Scholar
• . Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):e372–e382
   PubMedGoogle Scholar
• . Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wilholm BE. Dose-reponse relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326
   PubMed Web of Science ®Google Scholar
• . Cheetham TC, Levy G, Niu F, Bixler F. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warafin. Ann Pharmacother. 2009;43(11):1765–1773
   PubMedGoogle Scholar
• . Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31–40
   PubMed Web of Science ®Google Scholar
• . Rostom A, Muir K, Dubé C, . Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–828
   PubMed Web of Science ®Google Scholar
• . Steinbach G, Lynch PM, Phillips RK, . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–1952
   PubMed Web of Science ®Google Scholar
• . Arber N, Eagle CJ, Spicak J, . Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885–895
   PubMed Web of Science ®Google Scholar
• . Bertagnolli MM, Eagle CJ, Zauber AG, et al; for the APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–884
   PubMedGoogle Scholar
• . ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33
   Google Scholar
• . Silverstein FE, Faich G, Goldstein JL, . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–1255
   PubMed Web of Science ®Google Scholar
• . Davies NM, Longstreth J, Jamali F. Misoprostol therapeutics revisited. Pharmacotherapy. 2001;21(1):60–73
   PubMedGoogle Scholar
• . DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal relfux disease. Am J Gastroenterol. 2005;100(1):190–200
   PubMed Web of Science ®Google Scholar
• . Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738
   PubMed Web of Science ®Google Scholar
• . Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953
   PubMed Web of Science ®Google Scholar
• . FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) [press release]. Silver Spring, MD: US Food and Drug Administration; March 2, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. Accessed August 16, 2011
   Google Scholar
• . Tanzi MG. Managing GI issues in the rheumatology patient on chronic NSAID therapy. Pain Medicine News. 2010;37–44
   Google Scholar
• . Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol. 2010;26(6):611–617
   PubMed Web of Science ®Google Scholar
• . Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497
   PubMed Web of Science ®Google Scholar
• . Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable effifacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin. 2011;27(6):1243–1253
   PubMed Web of Science ®Google Scholar
• . Brewer AR, McCarberg B, Argoff CE. Update on the use of topical NSAIDs for the treatment of soft tissue and musculoskeletal pain: a review of recent data and current treatment options. Phys Sportsmed. 2010;38(2):62–70
   PubMed Web of Science ®Google Scholar
• . Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord. 2004;5:28
   PubMed Web of Science ®Google Scholar
• . Jorge LL, Feres CC, Teles VE. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res. 2010;4:11–24
   PubMedGoogle Scholar
• . Flector Patch (diclofenac epolamine topical patch) 1.3% [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2009
   Google Scholar
• . PENNSAID (diclofenac sodium topical solution) 1.55 w/w [package insert]. Hazelwood, MO: Mallinckrodt Inc.; June 2010
   Google Scholar
• . Voltaren Gel (diclofenac sodium topical gel) 1% [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2009
   Google Scholar
• . Hui X, Hewitt PG, Poblete N, Maibach HI, Shainhouse JZ, Wester RC. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res. 1998;15(10):1589–1595
   PubMedGoogle Scholar
• . Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010;50(1):50–61
   PubMed Web of Science ®Google Scholar
• . Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238–245
   PubMed Web of Science ®Google Scholar
• . Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (PENNSAID) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002–2012
   PubMed Web of Science ®Google Scholar
• . Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonstreoidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol. 2010;37(6):1236–1243
   PubMedGoogle Scholar
• . Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting—what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila). 2009;47(8):784–789
   PubMed Web of Science ®Google Scholar
• . Watkins PB, Kaplowitz N, Slattery JT, . Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93
   PubMed Web of Science ®Google Scholar
• . FDA Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. Silver Spring, MD: US Food and Drug Administration; January 13, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm239821.htm. Accessed August 16, 2011
   Google Scholar
• . Chan AT, Manson JE, Albert CM, . Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113(12):1578–1587
   PubMed Web of Science ®Google Scholar
• . Roth SH. A new role for opioids in the treatment of arthritis. Drugs. 2002;62(2):255–263
   PubMedGoogle Scholar
• . Schneider JP. Rational use of opioid analgesics in chronic musculoskeletal pain. J Musculoskel Med. 2010;27:142–148
   Google Scholar
• . Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–1978
   PubMedGoogle Scholar
• . Solomon DH, Rassen JA, Glynn RJ, . The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979–1986
   PubMed Web of Science ®Google Scholar
• . Kjaersgaard-Andersen P, Nafei A, Skov O, . Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomised, double-blind, multi-centre study. Pain. 1990;43:309–318
   PubMed Web of Science ®Google Scholar
• . Afilalo M, Etropolski MS, Kuperwasser B, . Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505
   PubMed Web of Science ®Google Scholar
• . Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005328
   Google Scholar
• . Raynauld JP, Buckland-Wright C, Ward R, . Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003;48(2):370–377
   PubMed Web of Science ®Google Scholar
• . Wen DY. Intra-articular hyaluronic acid injections for knee osteoarthritis. Am Fam Physician. 2000;62(3):565–570, 572
   PubMed Web of Science ®Google Scholar
• . Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues and future directions. J Rheumatol. 1998;25:2056–2058
   PubMedGoogle Scholar
• . Migliore A, Giovannangeli F, Granata M, Laganà B. Hylan g-f 20: review of its safety and efficacy in the management of joint pain in osteoarthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:55–68
   PubMedGoogle Scholar
• . Foti C, Cisari C, Carda S, . A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with osteoarthritis [published online ahead of print March 15, 2011]. Eur J Phys Rehabil Med
   Google Scholar
• . Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410–423
   PubMed Web of Science ®Google Scholar
• . Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford). 1999;38(7):602–607
   PubMed Web of Science ®Google Scholar
• . Henderson EB, Smith EC, Pegley F, Blake DR. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis. 1994;53(8):529–534
   PubMed Web of Science ®Google Scholar
• . Lundsgaard C, Dufour N, Fallentin E, Winkel P, Gluud C. Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. Scand J Rheumatol. 2008;37(2):142–150
   PubMed Web of Science ®Google Scholar